Carbinoxamine is a first generation antihistamine used to treat allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, allergic reactions, and mild allergic reactions. Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites.
- Mechanism
- Curator reviewed
Carbinoxamine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Carbinoxamine's anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
- Primary indication
- For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens.Curator reviewed · 8 structured indications
- Formula / weight
- C16H19ClN2O · 290.788 g/mol (avg)
- First approval
- United States, 2003
- Also known as
- Carbinoxamine base · Paracarbinoxamine
- Brand names
Resolves to
OJFSXZCBGQGRNV-UHFFFAOYSA-NSMILESCN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Carbinoxamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account